Omnicell (OMCL) to Release Quarterly Earnings on Wednesday

Omnicell (NASDAQ:OMCL) will release its earnings data before the market opens on Wednesday, October 30th. Analysts expect Omnicell to post earnings of $0.41 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. During the same period in the prior year, the firm earned $0.29 earnings per share. The business’s quarterly revenue was down 7.4% compared to the same quarter last year. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Omnicell Stock Performance

NASDAQ OMCL opened at $39.50 on Monday. The company has a fifty day moving average of $43.04 and a two-hundred day moving average of $34.71. The company has a market capitalization of $1.81 billion, a PE ratio of -85.87, a P/E/G ratio of 45.31 and a beta of 0.83. Omnicell has a 1 year low of $25.12 and a 1 year high of $45.84. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Wells Fargo & Company increased their target price on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Bank of America upped their price objective on shares of Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Benchmark restated a “buy” rating and set a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. JPMorgan Chase & Co. raised their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Finally, StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.33.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.